-
Je něco špatně v tomto záznamu ?
Performance of 8 Smoking Metrics for Modeling Survival in Head and Neck Squamous Cell Carcinoma
ACL. Lam, K. Hueniken, M. Pienkowski, JJW. Lee, M. Dong, B. Diergaarde, AF. Olshan, P. Brennan, S. Virani, D. Saunders, SA. Santi, MSC. Conlon, T. Waterboer, DN. Hayes, M. Pring, GJ. Macfarlane, P. Lagiou, A. Lagiou, J. Polesel, A. Agudo, L....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, multicentrická studie
Grantová podpora
001
World Health Organization - International
- MeSH
- dlaždicobuněčné karcinomy hlavy a krku * mortalita MeSH
- kouření cigaret * škodlivé účinky MeSH
- kouření * škodlivé účinky MeSH
- lidé středního věku MeSH
- lidé MeSH
- míra přežití MeSH
- nádory hlavy a krku * mortalita MeSH
- proporcionální rizikové modely MeSH
- retrospektivní studie MeSH
- rizikové faktory MeSH
- senioři MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
IMPORTANCE: Cigarette smoking is a strong risk factor for mortality in patients diagnosed with head and neck squamous cell carcinoma (HNSCC). However, little evidence supports which smoking metric best models the association between smoking and survival in HNSCC. OBJECTIVE: To determine which smoking metric best models a linear association between smoking exposure and overall survival (OS) in patients with HNSCC. DESIGN, SETTING, AND PARTICIPANTS: A retrospective multicenter cohort study of 6 clinical epidemiological studies was performed. Five were part of the Human Papillomavirus, Oral and Oropharyngeal Cancer Genomic Research (VOYAGER) consortium. Participants included patients 18 years and older with pathologically confirmed HNSCC. Data were collected from January 2002 to December 2019, and data were analyzed between January 2022 to November 2024. MAIN OUTCOMES AND MEASURES: The primary outcome was OS. The performance of 8 smoking metrics, including pack-years, duration, and log cig-years (calculated as log10[cigarettes smoked per day + 1] × number of years smoked) for modeling OS were compared. Metric performance was measured by the strength of association in Cox proportional hazard models, linearity based on P for linear trend, Akaike information criterion (AIC; lower value indicates better model fit), and visual assessment of spline curves. Secondary outcomes included modeling OS in clinicodemographic subgroups and HNSCC anatomic subsites. Exploratory outcomes included cancer-specific survival and noncancer survival. RESULTS: In total, 8875 patients with HNSCC (2114 [24%] female; median [IQR] age, 61 [54-69] years) were included. Of 8 smoking metrics evaluated, smoking duration (adjusted hazard ratio [aHR], 1.11 [95% CI, 1.03-1.19]) and log cig-years (aHR, 1.11 [95% CI, 1.04-1.18]) had the highest aHRs; both had a statistically significant linear association with OS. Log cig-years had the lowest AIC linear value and the most visually linear spline curve when modeling OS. Duration and log cig-years outperformed pack-years for modeling OS regardless of age, smoking status, and cancer stage. Both performed well in lip and oral cavity, laryngeal (only duration was significant), and human papillomavirus-negative oropharyngeal subsites. In an exploratory analysis, duration had the highest aHR (1.15 [95% CI, 1.02-1.29]), and log cig-years had the lowest AIC linear value when modeling noncancer survival. CONCLUSIONS AND RELEVANCE: In this cohort study, smoking duration and log cig-years best modeled a linear relationship with OS for patients with HNSCC. Both metrics maintained robust performance within specific clinicodemographic subgroups and anatomic subsites. Although most HNSCC survival models control for smoking exposure using smoking status or pack-years, duration and log cig-years may be superior metrics to account for the effects of smoking on survival.
Bristol Dental Hospital and School University of Bristol Bristol United Kingdom
Cancer Epidemiology Unit Department of Medical Sciences University of Turin Turin Italy
Catalan Institute of Oncology Barcelona Spain
Catalan Institute of Oncology Bellvitge Biomedical Research Institute Barcelona Spain
Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública Madrid Spain
Department of Medicine University of Toronto Toronto Ontario Canada
Department of Research Cancer Registry of Norway Norwegian Institute of Public Health Oslo Norway
Division of Infections and Cancer Epidemiology German Cancer Research Center Heidelberg Germany
Division of Medical Oncology Princess Margaret Cancer Centre Toronto Ontario Canada
Epidemiology Dalla Lana School of Public Health Toronto Ontario Canada
Health Sciences North Research Institute Sudbury Ontario Canada
International Agency for Research on Cancer Lyon France
Northern Ontario School of Medicine University Sudbury Ontario Canada
School of Dental Science Trinity College Dublin Dublin Ireland
School of Medicine Dentistry and Nursing University of Glasgow Scotland United Kingdom
School of Medicine National and Kapodistrian University of Athens Athens Greece
School of Public Health University of West Attica Athens Greece
Unit of Cancer Epidemiology Centro di Riferimento Oncologico di Aviano IRCCS Aviano Italy
University Bremen Bremen Germany
University of Padova Padova Italy
University of Tennessee Health Science Center Center for Cancer Research Memphis
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25016269
- 003
- CZ-PrNML
- 005
- 20250731091651.0
- 007
- ta
- 008
- 250708s2025 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1001/jamaoto.2024.5392 $2 doi
- 035 __
- $a (PubMed)39976935
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Lam, Andrew C L $u Department of Medicine, University of Toronto, Toronto, Ontario, Canada
- 245 10
- $a Performance of 8 Smoking Metrics for Modeling Survival in Head and Neck Squamous Cell Carcinoma / $c ACL. Lam, K. Hueniken, M. Pienkowski, JJW. Lee, M. Dong, B. Diergaarde, AF. Olshan, P. Brennan, S. Virani, D. Saunders, SA. Santi, MSC. Conlon, T. Waterboer, DN. Hayes, M. Pring, GJ. Macfarlane, P. Lagiou, A. Lagiou, J. Polesel, A. Agudo, L. Alemany, W. Ahrens, CM. Healy, DI. Conway, M. Nygard, C. Canova, A. Hornakova, L. Richiardi, A. Znaor, RJ. Hung, W. Xu, G. Liu
- 520 9_
- $a IMPORTANCE: Cigarette smoking is a strong risk factor for mortality in patients diagnosed with head and neck squamous cell carcinoma (HNSCC). However, little evidence supports which smoking metric best models the association between smoking and survival in HNSCC. OBJECTIVE: To determine which smoking metric best models a linear association between smoking exposure and overall survival (OS) in patients with HNSCC. DESIGN, SETTING, AND PARTICIPANTS: A retrospective multicenter cohort study of 6 clinical epidemiological studies was performed. Five were part of the Human Papillomavirus, Oral and Oropharyngeal Cancer Genomic Research (VOYAGER) consortium. Participants included patients 18 years and older with pathologically confirmed HNSCC. Data were collected from January 2002 to December 2019, and data were analyzed between January 2022 to November 2024. MAIN OUTCOMES AND MEASURES: The primary outcome was OS. The performance of 8 smoking metrics, including pack-years, duration, and log cig-years (calculated as log10[cigarettes smoked per day + 1] × number of years smoked) for modeling OS were compared. Metric performance was measured by the strength of association in Cox proportional hazard models, linearity based on P for linear trend, Akaike information criterion (AIC; lower value indicates better model fit), and visual assessment of spline curves. Secondary outcomes included modeling OS in clinicodemographic subgroups and HNSCC anatomic subsites. Exploratory outcomes included cancer-specific survival and noncancer survival. RESULTS: In total, 8875 patients with HNSCC (2114 [24%] female; median [IQR] age, 61 [54-69] years) were included. Of 8 smoking metrics evaluated, smoking duration (adjusted hazard ratio [aHR], 1.11 [95% CI, 1.03-1.19]) and log cig-years (aHR, 1.11 [95% CI, 1.04-1.18]) had the highest aHRs; both had a statistically significant linear association with OS. Log cig-years had the lowest AIC linear value and the most visually linear spline curve when modeling OS. Duration and log cig-years outperformed pack-years for modeling OS regardless of age, smoking status, and cancer stage. Both performed well in lip and oral cavity, laryngeal (only duration was significant), and human papillomavirus-negative oropharyngeal subsites. In an exploratory analysis, duration had the highest aHR (1.15 [95% CI, 1.02-1.29]), and log cig-years had the lowest AIC linear value when modeling noncancer survival. CONCLUSIONS AND RELEVANCE: In this cohort study, smoking duration and log cig-years best modeled a linear relationship with OS for patients with HNSCC. Both metrics maintained robust performance within specific clinicodemographic subgroups and anatomic subsites. Although most HNSCC survival models control for smoking exposure using smoking status or pack-years, duration and log cig-years may be superior metrics to account for the effects of smoking on survival.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a dlaždicobuněčné karcinomy hlavy a krku $x mortalita $7 D000077195
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 12
- $a nádory hlavy a krku $x mortalita $7 D006258
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a kouření $x škodlivé účinky $7 D012907
- 650 _2
- $a míra přežití $7 D015996
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a proporcionální rizikové modely $7 D016016
- 650 12
- $a kouření cigaret $x škodlivé účinky $7 D000073865
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Hueniken, Katrina $u Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
- 700 1_
- $a Pienkowski, Martha $u Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
- 700 1_
- $a Lee, John J W $u Department of Otolaryngology-Head and Neck Surgery, Sinai Health Systems, University of Toronto, Toronto, Ontario, Canada
- 700 1_
- $a Dong, Mei $u Department of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
- 700 1_
- $a Diergaarde, Brenda $u Department of Human Genetics, School of Public Health, University of Pittsburgh, and UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
- 700 1_
- $a Olshan, Andrew F $u Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill
- 700 1_
- $a Brennan, Paul $u Genetic Epidemiology Group, World Health Organization, International Agency for Research on Cancer, Lyon, France
- 700 1_
- $a Virani, Shama $u Genetic Epidemiology Group, World Health Organization, International Agency for Research on Cancer, Lyon, France
- 700 1_
- $a Saunders, Deborah $u Department of Dental Oncology, Shirley and Jim Fielding Northeast Cancer Centre, Health Sciences North, Sudbury, Ontario, Canada $u Northern Ontario School of Medicine University, Sudbury, Ontario, Canada
- 700 1_
- $a Santi, Stacey A $u Health Sciences North Research Institute, Sudbury, Ontario, Canada
- 700 1_
- $a Conlon, Michael S C $u Health Sciences North Research Institute, Sudbury, Ontario, Canada
- 700 1_
- $a Waterboer, Tim $u Division of Infections and Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
- 700 1_
- $a Hayes, D Neil $u University of Tennessee Health Science Center, Center for Cancer Research, Memphis
- 700 1_
- $a Pring, Miranda $u Bristol Dental Hospital and School, University of Bristol, Bristol, United Kingdom
- 700 1_
- $a Macfarlane, Gary J $u Epidemiology Group, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, Scotland, United Kingdom
- 700 1_
- $a Lagiou, Pagona $u School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
- 700 1_
- $a Lagiou, Areti $u School of Public Health, University of West Attica, Athens, Greece
- 700 1_
- $a Polesel, Jerry $u Unit of Cancer Epidemiology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy
- 700 1_
- $a Agudo, Antonio $u Catalan Institute of Oncology (ICO), and Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
- 700 1_
- $a Alemany, Laia $u Catalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain $u Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, Madrid, Spain
- 700 1_
- $a Ahrens, Wolfgang $u University Bremen, Bremen, Germany
- 700 1_
- $a Healy, Claire M $u School of Dental Science, Trinity College Dublin, Dublin, Ireland
- 700 1_
- $a Conway, David I $u School of Medicine, Dentistry, and Nursing, University of Glasgow, Scotland, United Kingdom
- 700 1_
- $a Nygard, Mari $u Department of Research, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway
- 700 1_
- $a Canova, Cristina $u University of Padova, Padova, Italy
- 700 1_
- $a Hornakova, Anna $u Institute of Hygiene & Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Richiardi, Lorenzo $u Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin, Turin, Italy
- 700 1_
- $a Znaor, Ariana $u International Agency for Research on Cancer, Lyon, France
- 700 1_
- $a Hung, Rayjean J $u Prosserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada
- 700 1_
- $a Xu, Wei $u Department of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
- 700 1_
- $a Liu, Geoffrey $u Medicine, Medical Biophysics, Pharmacology and Toxicology, Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada $u Epidemiology, Dalla Lana School of Public Health, Toronto, Ontario, Canada
- 773 0_
- $w MED00180929 $t JAMA otolaryngology - head & neck surgery $x 2168-619X $g Roč. 151, č. 4 (2025), s. 360-370
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39976935 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731091645 $b ABA008
- 999 __
- $a ok $b bmc $g 2366844 $s 1253394
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 151 $c 4 $d 360-370 $e 20250401 $i 2168-619X $m JAMA otolaryngology - head & neck surgery $n JAMA Otolaryngol Head Neck Surg $x MED00180929
- GRA __
- $a 001 $p World Health Organization $2 International
- LZP __
- $a Pubmed-20250708
